Table 2.
Age at Tumor and PPCM, Baseline and Follow-Up LVEF, Anticancer Treatment, and Genetic Variants in PPCM Patients With Cancer Before PPCM
| Patient # | Tumor Diagnosis | Age at Tumor Diagnosis (yrs) | Age at PPCM (yrs) | Baseline LVEF | Follow-Up LVEF | Anticancer Therapy | Genetic Variant (P/LP/VUS) |
|---|---|---|---|---|---|---|---|
| 01 | Breast cancer | 26 | 28 | 34 | 45 | Chemotherapy (cyclophosphamide, doxetaxel, doxorubicin), surgery, radiation |
DSP (P) DSG2 (VUS) |
| 02 | Breast cancer | 37 | 40 | 35 | 46 | Antihormone therapy, surgery, radiation | CPT2 (P) |
| 03 | Hodgkin lymphoma | 26 | 38 | 26 | 50 | Chemotherapy (bleomycin, cyclophosphamide, doxorubicin, etoposide, procarbazine, vincristine), radiation | BRCA1 (VUS) |
| 04 | Non-Hodgkin lymphoma | 20 | 24 | 30 | 30 | Chemotherapy (doxorubicin), radiation | TTN (VUS) |
| 05 | Acute myeloid leukemia | 13 | 34 | 45 | 45 | Chemotherapy (cytarabine, daunorubicin, doxorubicin, vincristine), radiation | MYBPC3 (VUS) |
| 06 | Osteosarcoma | 10 | 23 | 27 | 47 | Chemotherapy (cisplatin, methotrexate) |
MYH7 (LP) SLX4 (LP) |
| 07 | Osteosarcoma | 11 | 35 | 45 | 47 | Chemotherapy unknown composition |
2 variants in RECQL4 (LP/LP) 2 variants in FANCA (VUS/VUS) |
| 08 | Melanoma | 33 | 39 | 15 | 33 | Surgery | none |
| 09 | Hodgkin lymphoma | 17 | 36 | 40 | 45 | Radiation |
TTN (P) ATM (P) ERCC5 (P) |
| 10 | Non-Hodgkin lymphoma | 35 | 40 | 32 | 54 | Chemotherapy (adriamycin, cyclophosphamide, rituximab, vincristine) | TTN (VUS) |
| 11 | Acute lymphatic leukemia + melanoma | 4 | 31 | 20 | 36 | Chemotherapy (daunorubicin, doxorubicin) | TXNRD2 (VUS) ATM (VUS) |
| 12 | Acute lymphatic leukemia | 4 | 29 | 20 | 35 | Chemotherapy (adriamycin, dexamethasone, 6-mercaptopurin, methotrexate, vincristine), radiation |
Not performed |
Cardiac function at the time of diagnosis (baseline) and follow-up after PPCM in PPCM patients with malignancies before PPCM. Variants identified by exome sequencing are presented with their corresponding American College of Medical Genetics and Genomics class. All LP/P variants are in bold.
ATM = TM serine/threonine kinase; BRCA1 = breast cancer gene 1; CPT2 = carnitine-palmitoyltransferase II; DSG2 = desmoplakin; ERCC5 = excision repair cross-complementation group 5; FANCA = Fanconi anemia, complementation group; HTX = heart transplantation; LP = likely pathogenic; LVEF = left ventricular ejection fraction; MYBPC3 = cardiac myosin binding protein C; MYH7 = myosin heavy chain 7; P = pathogenic; PPCM = peripartum cardiomyopathy; RECQL4 = ATP-dependent DNA helicase Q4; SLX4 = structure-specific endonuclease subunit SLX4; TTN = titin; TXNRD2 = thioredoxin reductase 2; VUS = variant of unknown significance.